AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.710
-0.110 (-2.88%)
At close: Mar 3, 2026, 4:00 PM EST
3.700
-0.010 (-0.27%)
After-hours: Mar 3, 2026, 7:45 PM EST
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 7.75, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 108.89% from the current stock price of 3.71.
Analyst Consensus: Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $4 | Buy → Hold | Downgrades | $4 | +7.82% | Nov 7, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +88.68% | Aug 8, 2025 |
| Keybanc | Keybanc | Buy Maintains $5 → $10 | Buy | Maintains | $5 → $10 | +169.54% | Jul 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $5 | Buy | Initiates | $5 | +34.77% | Jul 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $10 | Strong Buy | Maintains | $28 → $10 | +169.54% | May 16, 2025 |
Financial Forecast
Revenue This Year
41.30M
from 75.13M
Decreased by -45.03%
Revenue Next Year
43.90M
from 41.30M
Increased by 6.30%
EPS This Year
-0.72
from -0.49
EPS Next Year
-0.75
from -0.72
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 60.9M | 72.5M | |||
| Avg | 41.3M | 43.9M | |||
| Low | 28.5M | 28.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -18.9% | 75.4% | |||
| Avg | -45.0% | 6.3% | |||
| Low | -62.1% | -30.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.65 | -0.64 | |||
| Avg | -0.72 | -0.75 | |||
| Low | -0.80 | -0.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.